Hims & Hers Health (HIMS) Cash from Operations Growth (1y) (2020 - 2026)
Hims & Hers Health (HIMS) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 81.06% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 8.26% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -46.22% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 63.59% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 73.78% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 33.73% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 16.88% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Hims & Hers Health | 7.81 Bn | 6.97 Bn | 480.80 Mn | -87.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -87.99% |
| Mar 31, 2026 | -18.09% |
| Dec 31, 2025 | -29.02% |
| Sep 30, 2025 | 74.42% |
| Jun 30, 2025 | -135.67% |
| Mar 31, 2025 | 322.21% |
| Dec 31, 2024 | 292.96% |
| Sep 30, 2024 | 238.48% |
| Jun 30, 2024 | 218.52% |
| Mar 31, 2024 | 172.47% |
| Dec 31, 2023 | 427.18% |
| Sep 30, 2023 | 320.90% |
| Jun 30, 2023 | 363.15% |
| Mar 31, 2023 | 148.87% |
| Dec 31, 2022 | -116.39% |
| Sep 30, 2022 | 137.50% |
| Jun 30, 2022 | -1,163.89% |
| Mar 31, 2022 | -21.66% |
| Dec 31, 2021 | -1,054.28% |
| Sep 30, 2021 | -608.93% |